Mostafa TM

ORCID: 0000-0003-1071-5416 · 1 paper in corpus

2025

A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial.

Current oncology (Toronto, Ont.) ·doi:10.3390/curroncol33010021

Background: The five-year survival rate of patients with ovarian cancer remains less than 50%, secondary to chemotherapy resistance. Purpose: This study aims to evaluate the effects of itraconazole as a supplementary treatment with paclitax…